Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZT006 in healthy, overweight and obese participants
NCT07307638Phase 1Completed
- Sponsor
- QL Biopharm
- Start
- Nov 2024
- Primary completion
- Jun 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZT006 in obesity (12 arms), sponsored by QL Biopharm. Primary endpoints: Treatment-Emergent Adverse Events after single dose administration under fasted condition at 43 days, Treatment-Emergent Adverse Events during and after multiple-dose administration at 77 days and 1 more. Started Nov 2024; status: completed.
02
Drugs
ZT006
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07307638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07307638.